Claims for Patent: 11,173,134

Summary for Patent: 11,173,134

Title:	Methods for the treatment of depression
Abstract:	The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).
Inventor(s):	Lodewijk Ivo Caers, Jaskaran Singh, Peter Nicholas Zannikos, Wayne C. Drevets, Ella Daly, Carla Marie Canuso, Margaret Fedgchin, Frank Wiegand
Assignee:	Janssen Pharmaceutica NV
Application Number:	US17/129,508
Patent Claims:	1. A method of treating major depressive disorder in a human patient in need thereof during a maintenance phase, wherein, optionally, the patient has already been treated with (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction phase of about four weeks, comprising intranasally administering an aqueous formulation comprising (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone and/or a pharmaceutically acceptable salt thereof in a maintenance dosage to provide a therapeutically effective amount of about 56 mg or about 84 mg of (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone, wherein the maintenance dosage is administered at a frequency of once per week or once every two weeks during the maintenance phase. 2. The method of claim 1, wherein the induction phase comprised intranasal administration of an aqueous formulation comprising (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone and/or a pharmaceutically acceptable salt thereof to the patient in an induction dosage to provide a therapeutically effective amount of about 56 mg or about 84 mg of (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone, and the induction dosage was administered at a frequency of twice per week during the induction phase. 3. The method of claim 2, wherein the maintenance phase continues until further treatment is not required as determined by a clinician or physician. 4. The method of claim 2, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 5. The method of claim 3, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 6. The method of claim 1, wherein the maintenance phase continues until further treatment is not required as determined by a clinician or physician. 7. The method of claim 1, wherein the maintenance phase comprises a treatment period of at least six weeks. 8. The method of claim 1, wherein the maintenance phase comprises a treatment period of at least eight weeks. 9. The method of claim 1, wherein the maintenance phase comprises a treatment period of at least twelve weeks. 10. The method of claim 1, wherein the maintenance phase comprises a treatment period of at least fourteen weeks. 11. The method of claim 1, wherein the maintenance phase further comprises adjunctive treatment with a therapeutically effective amount of one or more antidepressants. 12. The method of claim 11 wherein the major depressive disorder is treatment resistant depression or major depressive disorder with suicidal ideation or behavior. 13. The method of claim 1, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 14. The method of claim 12, wherein the one or more antidepressants is an oral antidepressant. 15. The method of claim 12, wherein the major depressive disorder is major depressive disorder with suicidal ideation or behavior. 16. The method of claim 15, wherein the maintenance phase continues until further treatment is not required as determined by a clinician or physician. 17. The method of claim 15, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 18. The method of claim 12, wherein the major depression disorder is treatment resistant depression. 19. The method of claim 18, wherein the maintenance phase continues until further treatment is not required as determined by a clinician or physician. 20. The method of claim 18, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 21. A method of treating treatment resistant depression in a human patient in need thereof during a maintenance phase, wherein, optionally, the patient has already been treated with (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction phase of about four weeks, comprising intranasally administering an aqueous formulation comprising (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone and/or a pharmaceutically acceptable salt thereof in a maintenance dosage to provide a therapeutically effective amount of about 56 mg or about 84 mg of (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone, wherein the maintenance dosage is administered at a frequency of once per week or once every two weeks during the maintenance phase. 22. The method of claim 21, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 23. The method of claim 21, wherein the maintenance phase continues until further treatment is not required as determined by a clinician or physician. 24. The method of claim 23, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 25. The method of claim 23, wherein the maintenance phase further comprises adjunctive treatment with a therapeutically effective amount of one or more oral antidepressants. 26. The method of claim 25, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 27. A method of treating major depressive disorder with suicidal ideation or behavior in a human patient in need thereof during a maintenance phase, wherein, optionally, the patient has already been treated with (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction phase of about four weeks, comprising intranasally administering an aqueous formulation comprising (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone and/or a pharmaceutically acceptable salt thereof in a maintenance dosage to provide a therapeutically effective amount of about 56 mg or about 84 mg of (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone, wherein the maintenance dosage is administered at a frequency of once per week or once every two weeks during the maintenance phase, wherein the maintenance phase continues until further treatment is not required as determined by a clinician or physician. 28. The method of claim 27, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase. 29. The method of claim 27, wherein the maintenance phase further comprises adjunctive treatment with a therapeutically effective amount of one or more oral antidepressants. 30. The method of claim 29, wherein the aqueous formulation comprises (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride during the maintenance phase.